Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

Ping Han Huang; Hsiao Han Tsai; Bo Hung Liao; Yi Ling Lin; Jia Tsrong Jan; Mi Hua Tao; Yu Chi Chou; Che Ming Jack Hu; Hui Wen Chen

doi:10.1080/21645515.2020.1814098

Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

Ping Han Huang, Hsiao Han Tsai, Bo Hung Liao, Yi Ling Lin, Jia Tsrong Jan, Mi Hua Tao, Yu Chi Chou, Che Ming Jack Hu, Hui Wen Chen

Center of Applied Nanomedicine

Research output: Contribution to journal › Comment/debate › peer-review

5 Citations (Scopus)

Abstract

A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

Original language	English
Pages (from-to)	654-655
Number of pages	2
Journal	Human Vaccines and Immunotherapeutics
Volume	17
Issue number	3
DOIs	https://doi.org/10.1080/21645515.2020.1814098
Publication status	Published - 2021

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Pharmacology

Access to Document

10.1080/21645515.2020.1814098

Cite this

@article{cf3053862bc0441dbab5f44c6a154a21,

title = "Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain",

abstract = "A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.",

author = "Huang, {Ping Han} and Tsai, {Hsiao Han} and Liao, {Bo Hung} and Lin, {Yi Ling} and Jan, {Jia Tsrong} and Tao, {Mi Hua} and Chou, {Yu Chi} and Hu, {Che Ming Jack} and Chen, {Hui Wen}",

note = "Publisher Copyright: {\textcopyright} 2020 Taylor & Francis Group, LLC.",

year = "2021",

doi = "10.1080/21645515.2020.1814098",

language = "English",

volume = "17",

pages = "654--655",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Landes Bioscience",

number = "3",

}

TY - JOUR

T1 - Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

AU - Huang, Ping Han

AU - Tsai, Hsiao Han

AU - Liao, Bo Hung

AU - Lin, Yi Ling

AU - Jan, Jia Tsrong

AU - Tao, Mi Hua

AU - Chou, Yu Chi

AU - Hu, Che Ming Jack

AU - Chen, Hui Wen

PY - 2021

Y1 - 2021

N2 - A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

AB - A safe and effective vaccine candidate is urgently needed for the ongoing COVID-19 pandemic, caused by SARS-CoV-2. Here we report that recombinant SARS-CoV-2 RBD protein immunization in mice is able to elicit a strong antibody response and potent neutralizing capability as measured using live or pseudotyped SARS-CoV-2 neutralization assays.

UR - http://www.scopus.com/inward/record.url?scp=85091731587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091731587&partnerID=8YFLogxK

U2 - 10.1080/21645515.2020.1814098

DO - 10.1080/21645515.2020.1814098

M3 - Comment/debate

AN - SCOPUS:85091731587

SN - 2164-5515

VL - 17

SP - 654

EP - 655

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 3

ER -

Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this